PHILADELPHIA, PA – 23 June, 2011 ERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today that Robert Kleiman, M.D. has been appointed to the role of Chief Medical Officer in addition to his current role as Vice President of Global Cardiology.
Dr. Kleiman graduated from Brown University Medical School with residency in Internal Medicine and completed Fellowships in Cardiology and Cardiac Electrophysiology at the University of Pennsylvania. Prior to joining ERT as a full time employee in April 2004, Dr. Kleiman had worked for ERT as an independent contractor through his cardiology and cardiac electrophysiology practice since 1994. Dr. Kleiman has managed ERT’s cardiology group, which has more than tripled in size since 2004, while maintaining ERT’s standards for high quality and consistency.
In addition to his current duties as Vice President of Global Cardiology, Dr. Kleiman will be responsible for assuming an increasing consulting and sales role. “Dr. Kleiman combines remarkable industry expertise with years of experience in the hospital practice environment. These factors, coupled with his in-depth knowledge of our business operations, make him a perfect candidate for the position,” commented Dr. Jeffrey Litwin, President and Chief Executive Officer of ERT. “I would like to thank Bob for his dedicated service over the past eight years and congratulate him on this well deserved promotion. All of our employees look forward to continuing to work with him as he expands his role at ERT”.
Commenting on his appointment Dr Kleiman noted, “I have enjoyed my long association with ERT and very much look forward to working with our customers and staff in my new role of working more closely with sponsors to ensure the efficacy and safety of new drugs”.
For further information on ERT and its technology and services, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.co.uk.
About ERT
ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations. It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company’s ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Media Contacts:
Fiona Robinson
The Scott Partnership
Tel: +44 1477 539539
ert@scottpr.com
John Blakeley
ERT
+1 215 972 0420
jblakeley@ert.com
PRFilter
PRFilter is a relevance engine that filters press releases for users based on a personal profile of their interests created from their own, or their publication’s, published articles. The public website also provides anyone with the ability to search thousands of releases from multiple sources or view the most relevant releases in particular areas of interest.
Releases marked with [PRFilter] in the subject line of RealWire release emails indicate PRFilter determined the release passed an individuals relevance threshold. Users can login and increase or decrease this threshold. Users can also train PRFilter to determine release relevance more accurately by providing feedback – “More”, this release is relevant or “Less”, this release is not relevant.
Please visit PRFilter to log in or contact RealWire for more information.
News Receiver Options
Receivers members area – the receivers members area allows you to amend your news category options and preferences, and access your own personal RSS feed of relevant news. Log in now or request log in details.
Unsubscribe – should you wish to unsubscribe from RealWire’s distribution, please click here. We would very much value your feedback on why you wish to be removed in order for us to continue to improve and develop our service.
Disclaimer:
Whilst RealWire Limited endeavour to ensure the accuracy of the information contained in this Release, RealWire Limited cannot accept any liability for:-
- the inaccuracy or otherwise of any information contained in this Release; or
- any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release; or
- any loss or suffering which may be caused by or to any party either as a result of the information contained in this
Release or such information contained in this Release being inaccurate or otherwise misleading.
In the event that any information contained in this Release is inaccurate or misleading then please contact RealWire.
RealWire’s privacy policy is available on our website.
RealWire:
The registered address of RealWire is:
Realwire Limited, Unit 1, Exchange Close, North Hykeham, Lincoln, LN6 3TR.
Realwire Limited is a company registered in England and Wales: 4026690
